Kornimate/medical-research-clean huggingface dataset:
effect of pumpkin seeds phonophoresis on chronic non-bacterial prostatitis

Conditions: Chronic Non-bacterial Prostatitis

Summary: it has been observed that out of all visits to the clinics by the young and middle age men for grievances including the genital and urinary frameworks, about 25% of the visits account for prostatitis. a significant number of men, aged less than 50, visits to urologist due to interminable prostatitis. nevertheless, just 5 to10% of "prostatitis" cases is really caused by a bacterial contamination. the purpose was to investigate thoroughly the effect of pumpkin seeds oil phonophoresis among males who are diagnosed with chronic non-bacterial prostatitis.

sixty male outpatients diagnosed with chronic non-bacterial prostatitis. through sample random sampling procedure the total study population was categorized into three treatment groups; group a, wherein patients received phonophoresis treatment using pumpkin seeds oil; group b, where members of the group received trans-perineal continuous low-intensity ultrasound; and group c, in which the participant received placebo low- intensity ultrasound. all of the three groups of the organized trail received their corresponding treatment daily up-to 3 weeks. for the analysis participants were recruited from a registry of patients with a diagnosis of cnbp. to be included in the analysis a patient must be evaluated with a confirmed diagnosis. they were examined and diagnosed accordingly by a medical practitioner/urologist. patients with concomitant infection, autoimmune diseases, diabetes mellitus, cancer, heart problems/pacemaker, implants (metal, silicone, saline), acute and post-acute injury, thrombophlebitis, impaired sensation, psychiatric diseases, and those with well-known contraindications of ultrasound treatment were excluded from the study. similarly, those with known hypersensitivity to pumpkin seeds oil and its derivatives, along with those who had received other forms of therapies that could influence the therapeutic outcomes of the study were excluded from the study sample.

Eligibility criteria:
inclusion criteria: * for the analysis participants were recruited from a registry of patients with a diagnosis of cnbp. to be included in the analysis a patient must be evaluated with a confirmed diagnosis. they were examined and diagnosed accordingly by a medical practitioner/urologist. the patients who were included in the study should have normal laboratory findings exclusion criteria: * patients with concomitant infection, autoimmune diseases, diabetes mellitus, cancer, heart problems/pacemaker, implants (metal, silicone, saline), acute and post-acute injury, thrombophlebitis, impaired sensation, psychiatric diseases, and those with well-known contraindications of ultrasound treatment were excluded from the study. similarly, those with known hypersensitivity to pumpkin seeds oil and its derivatives, along with those who had received other forms of therapies that could influence the therapeutic outcomes of the study were excluded from the study sample.
safety and tolerability of repeated subcutaneous injections of cad106 in mild alzheimer's patients.

Conditions: Alzheimer Disease

Summary: this study will evaluate the safety and tolerability of repeated subcutaneous injections of cad106 in patients with mild alzheimer's disease.


Eligibility criteria:
inclusion criteria: * diagnosis of mild alzheimer's disease * mini-mental state examination (mmse) 20 to 26 at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 6 weeks exclusion criteria: * previously participated in an ad vaccine study and received active treatment * history or presence of an active autoimmune and/or with an acute or chronic inflammation, and/or clinically relevant atopic condition. * history or presence of seizures and/or cerebrovascular disease. * presence of an other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)

Keywords: active immunization alzheimer disease antibody central nervous system diseases neurodegenerative diseases vaccine
the effects of nitazoxanide in hepatic encephalopathy

Conditions: Hepatic Encephalopathy

Summary: evaluating the efficacy and safety of nitazoxanide in comparison to standard treatment in patients with grade ii-iii hepatic encephalopathy (he). also, evaluating the effect of administering nitazoxanide on the improvement of patient's quality of life.

nitazoxanide (ntz) is a thiazolide anti-infective with activity against anaerobic bacteria, protozoa and viruses. a pilot prospective study at the 2008 american association for the study of liver diseases meeting showing clinical improvement in he among cirrhotic patients who received nitazoxanide and lactulose. based on the excellent safety profile of ntz, the present pilot study is conducted hopefully to prove the efficacy of nitazoxanide in treating patients experiencing he grade ii-iii. study design:the study is prospective, randomized, controlled, open-label, pilot study. method: the study will include a total of 36 patients with grade ii-iii hepatic encephalopathy, and an informed consent will be obtained from every patient before being included. all the patients will receive oral lactulose, plus either nitazoxanide, metronidazole or rifaximine. a- all patients will be subjected to the following at baseline: * patient's full history * liver disease staging using model for end stage liver disease (meld) score * measurement of serum electrolytes (na+, k+, ca2+) b- all patients will be subjected to the following at baseline and at the end of treatment: * measuring blood ammonia level * measuring liver function tests (ast, total bilirubin, international normalized ratio (inr), serum albumin, prothrombin time (pt)), serum creatinine and complete blood count (cbc) * assessing severity of hepatic encephalopathy using clinical hepatic encephalopathy staging scale (chess) c- monitoring tolerability up to 30 days after the last dose d- assessment of quality of life using chronic liver disease questionnaire (cldq)

Eligibility criteria:
inclusion criteria: * adult patients from 18 to 65 years. * patients with grade ii-iii hepatic encephalopathy. exclusion criteria: * patients with active git bleeding. * patients with major psychiatric illness. * patients receiving benzodiazepines, narcotics, alcohol and marijuana. * patients with compromised renal or biliary functions. * patients known to have aids. * patients receiving medications highly bound to plasma proteins eg. warfarin. * patients with known hypersensitivity to nitazoxanide. * pregnant or lactating women.

Keywords: hepatic encephalopathy nitazoxanide serum ammonia
a personalized trunk stability exercise program study with brain disease patients

Conditions: Brain Diseases

Summary: to investigate the effect on improving trunk stability and satisfaction with the program when a customized trunk stabilization exercise program personalized to the subject's functional level is applied to patients with brain disease.


Eligibility criteria:
inclusion criteria: 1. adults over 19 years old 2. brain disease patients hospitalized in the rehabilitation medicine department of our hospital and receiving exercise therapy 5 times a week 3. patients with a functional ambulatory category (fac) score of 0-4 4. after receiving a detailed explanation of this study and fully understanding it, the subject or legal representative voluntarily decides to participate and agrees in writing to follow the precautions. exclusion criteria: 1. those who have suffered prior to participating in the study 2. those in good physical condition, such as unstable conditions in the state system, coordination system, problem system, and endocrine system, and those with cerebrovascular disease 3. other cases of investigation without participation in this study
long term bowel function following rectal cancer surgery

Conditions: Bowel; Functional Syndrome; Rectal Cancer

Summary: * in this longitudinal study, 171 patients were evaluated and compared based on the radiation therapy they received. * bowel function was assessed longitudinally with memorial sloan kettering cancer center and wexner scores every 6 months after restoration of bowel continuity. patients with at least two follow-up visits were included.

background despite advances in the neoadjuvant chemoradiation therapy and anal sphincter-preserving surgeries for rectal cancer, bowel dysfunction is still unavoidable which negatively affect the patients' quality of life. in this longitudinal study, the aim of this study was to investigate the changes in bowel function with follow up time and the effect of the neoadjuvant chemo radiotherapy on bowel function following low anterior resection for rectal cancer. materials and methods in this study, 171 patients with rectal cancer who underwent low anterior resection between 2012 and 2018 were included. bowel function was assessed longitudinally with memorial sloan kettering cancer center and wexner scores every 6 months after restoration of bowel continuity. patients with at least two follow-up visits were included.

Eligibility criteria:
inclusion criteria: * patients of both sexes, * aged between 18 and 75 years, * patients with mid and upper rectal cancer (6-15) cm from the anal verge(av) with or without preoperative chemo radiotherapy. * patients who underwent low anterior resection(lar). * patients who were followed up with at least two outpatient visits for bowel function assessment. exclusion criteria: * patients with recurrent rectal tumors, * surgically unfit patients, * patients with tumors infiltrating the puborectalis muscle or external sphincter. * patients with preoperative fecal incontinence. * patients who were followed up only once in the outpatient clinic. * patients with lower rectal cancer less than 6cm from av, * patients who underwent abdominoperineal resection(apr) or intersphincteric resection(isr).

Keywords: rectal cancer sphincter preserving surgery neoadjuvant therapy ow anterior resection syndrome
nesiritide - dilated cardiomyopathy

Conditions: Dilated Cardiomyopathy

Summary: nesiritide is a rapid vasodilator that mimics the action of an endogenous hormone - human b-type natriuretic peptide (bnp). bnp is produced naturally in the ventricles of the heart in response to stretch. nesiritide decreases systemic vascular resistance (svr), pulmonary capillary wedge pressure (pcwp), right atrial pressure (rap), and mean pulmonary arterial pressure. nesiritide does not affect the heart rate, but does increase the stroke volume and consequently cardiac output, resulting in a decrease in the symptoms of decompensated heart failure. it is generally well tolerated, with the major negative side effect being hypotension. when compared to standard therapy consisting of dobutamine and nitroglycerin, nesiritide had similar vasodilatory effects, but showed a lower incidence of arrhythmia. nesiritide has been approved for iv treatment of patients with acutely decompensated congestive heart failure. although studies have tested the effectiveness and safety of nesiritide in adult chf patients, this has not been done in children. subjects enrolled in this study will be pediatric (\<21 years) patients carrying a diagnosis of dilated cardiomyopathy with decompensated congestive heart failure. the standard of care for these patients is to undergo cardiac catheterization with placement of a swan-ganz catheter for hemodynamic monitoring. subjects will be randomly assigned to receive either nesiritide or placebo (5% dextrose). the infusion will then be continued for a total of twenty-four hours. during this one day period, measurements of systemic blood pressure, central venous pressure (right atrial pressure), pulmonary capillary wedge pressure, cardiac output, mixed venous saturation, pulmonary vascular resistance, and systemic vascular resistance will be measured at regularly scheduled intervals. the swan-ganz catheter will remain in place for 2 hours after the discontinuation of study drug, and then removed. the objectives of this study are: 1. to assess the efficacy of nesiritide therapy in decreasing the pulmonary capillary wedge pressure, right atrial pressure, and systemic vascular resistance in children with dilated cardiomyopathy. 2. to assess the efficacy of nesiritide in decreasing pulmonary edema and increasing cardiac index in the above mentioned population. 3. to assess the safety of both bolus administration and continuous infusion of nesiritide in children with dilated cardiomyopathy. 4. to assess the pharmacokinetics of nesiritide in this population.


Eligibility criteria:
inclusion criteria: 1. diagnosis of dilated cardiomyopathy 2. less than 21 years of age 3. patient admitted to the intensive care unit 4. patient requiring placement of a swan-ganz catheter 5. patient's hemodynamics or clinical condition requires the use of a swan-ganz catheter for 26 hours following the cardiac catheterization. 6. patient has signed an irb approved consent form. exclusion criteria: 1. severe hemodynamic instability including patients requiring ecmo 2. cardiac catheterization not indicated

Keywords: pediatric dilated cardiomyopathy nesiritide
the impact of endoscopic pituitary surgery on nasal function

Conditions: Pituitary Tumor; Endoscopic Surgery; Quality of Life; Function of Nose

Summary: the aim of this study is to determine the impact of endoscopic transsphenoidal pituitary surgery on nasal function using a numerical simulation and to compare the difference between two kinds of transsphenoidal approachese(single nostril approach and bilateral nostril approach)．

neuroendoscopic surgery is the first treatment for most pituitary adenoma patients. because transsphenoidal surgery exploits the nasal corridor and paranasal sinuses to reach the skull base, sinonasal trauma is a primary source of postoperative morbidity in many of these patients. the aim of this study is to determine the impact of endoscopic transsphenoidal pituitary surgery on nasal function using a numerical simulation and to compare the difference between two kinds of transsphenoidal approachese(single nostril approach and bilateral nostril approach)．

Eligibility criteria:
inclusion criteria: 1. enhanced mri shows a pituitary tumor 2. endoscopic surgery is required according to the pituitary tumor treatment guidelines. 3. karnofsky performance status ≥ 70. 4. the patient has signed the informed consent. exclusion criteria: 1. patients who have undergone previous transsphenoidal surgery or other nasal surgery. 2. patients who had a history of nasal tumors. 3. patients who had a history of severe head or face trauma. 4. patients with congenital sinus malformation. 5. pregnant or lactating women. 6. patients with serious systemic diseases without control. 7. patients with poor compliance, who cannot implement the program strictly.

Keywords: pituitary tumor neuroendoscope surgical approach computational fluid dynamics numerical simulation
treatment of chronic frontal sinusitis by a simple technique using dilation balloons

Conditions: Frontal Sinusitis

Summary: the sinuplasty balloon offers a more physiological first of the sinuses which minimizes risks associated to traditional surgery. its atraumatic characteristic also helps to reduce the risk of bleeding (so any use of pack), limit scarring ransom, reduce the post-operative pain, ensure faster return to daily life activities (reduction of the average length of hospitalization). patient's quality of life would be improved (snot-22 questionnaire) and reduction of post-operative pain score seams decrease on eva. the economic impact of the sinuplasty balloon appears very favourable and fits into the strategy of development of the ambulatory practice.

the primary objective is to estimate the cost-utility ratio of the sinuplasty balloon after frontal sinus surgery, compared to surgery by rigid instrumentation, in a randomized single-blind controlled study. the secondary objectives is to compare: * the two types of surgery * the quality of life * the feeling of pain in patients but also the occurrence of surgical times or complications between the two proposed techniques.

Eligibility criteria:
inclusion criteria: * man or woman of age ≥ to 18 years. * patient for which a frontal sinus surgery (draf 1 type) is programmed for any type of frontal sinusitis unresponsive to drug treatment properly leads. * patient affiliated to a social protection scheme written informed consent of the patient * signed informed consent exclusion criteria: * polyposis sinonasal or other sinus to be the subject of a simultaneous complementary intervention * sinuso-nasal tumors * osteogenesis * fragile patients or patient needing gesture contraindicating surgery by rigid instrumentation * contraindication with balloon using * contraindication to general anesthesia * immunosuppressive therapy * patient under judicial protection * pregnancy or breastfeeding * exclusion period determinated with concurrent participation in other experimental studies * contrast medium allergy background * impossibility to give the informed study documentation to the subject (emergency situation, lack of understanding, etc...)
australian trial in acute hepatitis c recall study

Conditions: Acute Hepatitis C

Summary: a single long-term follow up assessment of an established multi-centre, prospective longitudinal cohort study of patients for clinical, psychosocial, immunovirological outcomes 4 to 8 years after previous treatment for recently acquired hepatitis c virus infection.

the study aims are: 1. to evaluate the effect of successful prior treatment or spontaneous clearance of recently acquired hcv infection on long-term quality of life, social functioning, injecting behaviour, mental health and liver health. 2. to assess the incidence of hcv re-infection following prior treatment induced clearance or spontaneous clearance of recently acquired chronic hcv infection. 3. to determine predictors of hcv re-infection following recently acquired hcv infection treatment. 4. to determine frequency and predictors of new mixed and superinfections in atahc subjects with persistent viraemia. 5. to add to a tissue repository of serum and pbmcs from well-characterised patients treated for recently acquired hcv infection to allow future examination of the role of other variables that may potentially impact on the prognosis and outcomes of early hcv treatment.

Eligibility criteria:
inclusion criteria: * previous enrolment in the australian trial of acute hepatitis c virus infection (atahc) study. * provision of written, informed consent. exclusion criteria: * in the opinion of the investigator that the patient is not able to provide informed consent. * inability or unwillingness to comply with study collection requirements.

Keywords: hepatitis c acute early chronic
the effect of trimetazidine on mitochondrial function, myocardial performance, and invasive hemodynamics in patients diagnosed with wild-type transthyretin cardiac amyloidosis

Conditions: Transthyretin Amyloid Cardiopathy; Mitochondrial Pathology

Summary: wild-type transthyretin cardiac amyloidosis (attrwt) is a deposition disorder in which one of the proteins of the body misfolds and accumulates at various places in the body, including the heart, leading to both mechanical and cellular damage. the gradual development of the disease will ultimately lead to heart failure and death the protein which deposits in the heart of patients, damages both the heart mechanically as the myocardium becomes rigid and hypertrophic over time but also at the cellular level. cell damage can be observed by elevated blood tests for cell damage (troponin) and during exercise tests that show patients' hearts burning oxygen inefficiently when exposed to physical stress compared with the hearts of healthy individuals . no one has, however, intimately studied this cellular damage. vastarel® (trimetazidine, tmz) is an already known drug for the treatment of chest pain. the mechanism of action indicates that it may have an effect on patients with cardiac amyloidosis. the study aims to investigate the effects of tmz on the mitochondrial function, myocardial performance, and invasive hemodynamics in patients with attrwt with a randomized, double-blinded, crossover-trial.


Eligibility criteria:
inclusion criteria: * wild-type transthyretin cardiac amyloidosis * nac stage i * nyha class of i or ii * informed consent exclusion criteria: * other, similar diagnoses * hereditary transthyretin cardiac amyloidosis * light chain amyloidosis * morbus waldenstrøm * myelomatosis * medical treatment with loop diuretics in standard doses (40 mgx1 daily) * contraindications to trimetazidine * significant comorbidity assessed by the investigators * unable to provide informed consent
influence of the surgical approach on the development of a chronic pain after thoracic surgery

Conditions: Pain, Postoperative

Summary: the prevalence of chronic pain after a thoracotomy is around 48 %. this research focuses on the surgical approach. the posterolateral approach is compared to the axillary approach especially in term of development of a chronic pain.


Eligibility criteria:
inclusion criteria: * patients undergoing thoracic surgery intervention by posterolateral or axillary thoracotomy, having no exclusion criteria for the study, exclusion criteria: * planned surgery by thoracoscopy or extended surgery, * mental disability, * vulnerable person within the meaning of french law, * inability to communicate by phone, * poor understanding of french.